Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MRNA quick ut, 1.27 x 1.28
FYI. wanted to round out my stack put a bid in at .0009 just an hour ago or so and it just filled. 265k only. Was hoping it wouldn't have been that easy.
about to blow here, no brainer IMO. Check out the chart.
MRNA about to blow here, no brainer IMO. Check out the chart.
MRNA, no brainer here, IMO
Yep, thats an even better example. Lol, wow I forgot about that one. The more I think about it, the idea of JD purposly tanking this is becoming more plausable. You would have to go out of your way to do some of the bonehead things he's done.
"I'm not that smart but JD seemed to help the effort ...."unknowingly"?
Good example of this was when he pr'd the update on the milestone project about a month ago. Nice news, spiked nicely to .0018 or so and looked like it was going to be a solid reversal and run. Nope, he immediatly follows it up with an AS increase pr the next day I believe. I mean c'mon, you finally do something to get the pps to reverse it's nasty downfall and you follow it up with that??? Nobody can be that stupid can they? He had to purposly do that so the pps would fall back down not???
Why would things change just because supposedly a new CEO is coming in??? If they wanted to be transparent why wouldn't they have done it while that doufus JD was at the helm. There's really only 2 reasons it can be.
1- Maybe they wanted the pps to dive to the basement like it did for some reason. Maybe to load some people up with cheap shares or something I don't know. It's hard to believe that even JD can be as stupid as he appears to be. He could have turned this around long ago by doing just a few simple things but chose not to. They might be sitting on some giant news or maybe even finiancials that actually show his projections of 4-6mil were in line but simply haven't released them so the price would drop. Well, they got there cheap shares now.
or
2- JD dug a hole so deep with lies and false projections that he couldn't come clean.
There keeping key info away from the public for a reason, after alot of it was promised months ago. You just wouldn't do that unless you did something wrong or possibly because of the previously mentioned.
I'd say the chance of it being the first reason are very slim but regardless, I've been a buyer at .0008 & .0009.
MRNA breaking down 1.25, might go here
added MRNA, chart looking ready for next move up, Golden Cross coming. Could see big pharma news any day IMO
added MRNA, chart looking ready for next move up, Golden Cross coming. Could see big pharma news any day IMO
waking up....
MRNA tried to add at 1.26, no dice
Yeah it aint
WAVE looks like it may be for real this time
MRNA gapping in pre-market, not sure why. Someone knows something I assume
.0008's a coming!!!!
Just a market correction. It was very overbought and needed a breather. Look for it to stabilize in the 1.30's
WAVE good for a nickel flip and thats about it it seems. That HOD print at .4879 was a partial sell of mine. Bastards couldn't take it all. Crazy how it spikes about once a day and immediatly sells back off to .44 or so. Don't know what to make of it.
Me neither, bid was in at .1506
AVOE .21, this move sort of looking for real here.
MRNA uting into close, people finally realizing how rediculous it is to sell at these levels
??????????
AVOE .11 POS looks like it may go here.
VRAL, break .06 and it's party time IMO
yep, my thoughts exactly
MRNA bouncing off 200, excellent buy opp there
Added MRNA 1.18 looking for a bounce off the 200
Boards a little dead today, early weekend for everyone?
Added MRNA 1.18
MRNA buy opp here IMO
Dammit, should have flipped WAVE again for a nickel
WAVE getting some love this a.m., pressure is mounting
added more MRNA, this baby is gonna blow up big one of these days
ULU gap filled, lets see if it can do anything here on news
ULURU Inc. to Present Altrazeal(TM) Clinical Evidence at the 23rd Annual Symposium on Advanced Wound Care and Wound Healing Society (SAWC/WHS)
-Follows Highly Successful Oral Presentation at the 2010 American Professional Wound Care Association Conference
prnewswire
*
Companies:
o ULURU Inc.
Press Release Source: ULURU Inc. On Thursday April 15, 2010, 8:00 am
ADDISON, Texas, April 15 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Amex: ULU) announced today that the company will present clinical evidence at the 2010 joint annual meeting of the Symposium on Advanced Wound Care and the Wound Healing Society (SAWC/WHS) in Orlando, Florida, April 17-20. SAWC/WHS is the premier wound care educational program within this clinical field and is the largest annual gathering of wound care clinicians in the United States. More than 2,000 physicians, podiatrists, nurses, therapists, and researchers are expected to attend the 2010 SAWC/WHS meeting. In addition to the presentation of the clinical evidence, the Company will also be providing educational guidance, showcasing advanced research on Altrazeal™ and products in the Altrazeal™ pipeline.
Posters detailing application techniques and clinical care with Altrazeal™ in all major wound types, including diabetic foot, pressure and venous ulcers, will be presented to show how the product can be used in practice to treat these wounds.
Altrazeal™ has shown a statistically significant decrease in pain in a randomized controlled clinical study. This effect is further demonstrated in a case study detailing pain management in patients with venous ulcers, to be presented by Catherine T. Milne, APRN, MSN, BC-ANP, CWOCN of Connecticut Clinical Nursing Associates, LC Bristol Hospital Wound, Ostomy, Lymphedema Center Bristol, Connecticut. Ms. Milne stated, "Wound pain is a tremendous burden for these patients. Having found a topical, cost effective method to reduce pain enhances patient compliance in wound care."
Details of how to incorporate Altrazeal™ into the home healthcare practice, including patient selection and clinical protocols, will be demonstrated in a poster authored by Bobbie Spitz, RN CNS - BC CWS of the Aurora Visiting Nurse Association of Wisconsin in Milwaukee, Wisconsin. The poster titled, "Patient Selection and Incorporation of a Novel Transforming Powder Dressing in Home Healthcare" describes cost benefits and nursing time benefits to be derived using Altrazeal™ in certain patient populations.
A number of clinical posters by Greg Bohn, MD, FACS, Medical Director of the Trinity Center for Wound Care and Hyperbaric Medicine in Bettendorf, Iowa, explain multiple case studies where Altrazeal™ has been used successfully in difficult to heal wound types. Also, a poster describes how utilizing total contact casts with Altrazeal™ may shorten days to heal in neuropathic diabetic foot ulcers. Another poster will detail cases where techniques were developed to incorporate Altrazeal™ in the treatment of pressure ulcers, with pain and moisture management, in this difficult to treat class of wounds.
These poster presentations by Dr. Bohn follow his well-attended podium presentation at the American Professional Wound Care Association (APWCA) national conference on Saturday, April 10th. The presentation titled "Transforming Powder Wound Dressing Relieves Pain and Manages Moisture, Restoring Quality of Life" generated significant audience participation in a question and answer session following the presentation, generating very positive feedback on the attributes of Altrazeal™.
Renaat Van den Hooff, President and CEO of ULURU Inc., commented, "The clinical experience data that will be presented at the SAWC/WHS Symposium is compelling and highlights the clinical, pharma-economic and patient benefits that Altrazeal™ provides. This event comes only a week after a highly successful presentation of clinical evidence and Dr. Bohn's presentation at the APWCA conference. These meetings allow more and more clinicians to discover the benefits that Altrazeal™ provides."
ULURU will also present a poster detailing the preclinical and formulation development of Altrazeal Collagen, a new and important addition to the Altrazeal™ family of products.
A set of three advanced technology Altrazeal™ posters have also been accepted for presentation at the prestigious Wound Healing Society Blue Ribbon Poster contest. These posters include a technique for moisture management of living skin equivalent constructs when combined with Altrazeal, details surrounding the effectiveness and importance of intimate contact between Altrazeal™ Silver and tissue and a poster on an innovative Nanoflex™ technology advancement utilizing ULURU's gel formulation as a tunneling wound gel.
ULURU will also be present at the SAWC/WHS conference with a booth in the exhibit space to provide information on Altrazeal™ application techniques, best clinical experiences and the patient and economic benefits to be derived using Altrazeal™.
Information about SAWC/WHS and the annual spring meeting can be found at spring.sawc.net
About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex™ Aggregate technology and OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com. For further information about Altrazeal™, please visit www.Altrazeal.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the benefits, effectiveness, biocompatibility, ease of application, success in wound healing, clinical outcomes, reimbursement and suitability of Altrazeal™, and the success of our clinical efforts. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, and other reports filed by us with the Securities and Exchange Commission.
Contact: Company
Renaat Van den Hooff
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5
Test previous highs today and then see a pullback finally IMO
Very impressive today how this is holding it's gains over the past week. I sold at $1.66 today thinking that it had to take a breather and pullback some but didn't happen. This stock is strong!
Never traded at .14 today.
i added today
ULU gonna test HOD here before EOD IMO